Molecular Formula | C29H38N2O6.HCl |
Molar Mass | 547.08 |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
In vitro study | Atrasentan hydrochloride (ABT-627 hydrochloride) (0-50 μM) significantly inhibits LNCaP and C4-2b prostate cancer cell growth. Atrasentan profoundly induces several CYPs and drug transporters (e.g. 12-fold induction of CYP3A4 at 50 μM). It is a moderate P-gp inhibitor (IC 50 in P388/dx cells=15.1±1.6 μM) and a weak BCRP inhibitor (IC 50 in MDCKII-BCRP cells=59.8±11 μM). |
In vivo study | Atrasentan hydrochloride (ABT-627 hydrochloride) (3 mg/kg, p.o.) inhibits the pressor response induced by big endothelin-1 (1 nmol/kg) in pithed rats. Aatrasentan (ABT-627, 10 mg/kg, i.p.) inhibits the C4-2b tumor growth within the bone environment to some extent in the SCID-hu model. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.828 ml | 9.139 ml | 18.279 ml |
5 mM | 0.366 ml | 1.828 ml | 3.656 ml |
10 mM | 0.183 ml | 0.914 ml | 1.828 ml |
5 mM | 0.037 ml | 0.183 ml | 0.366 ml |